Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 118

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 118
---
 rate of 0.5% of the amount or value of the consideration. If it is necessary to pay stamp duty, it may also be necessary to pay interest and penalties.

<div align='center'>S-65</div>

TABLE OF CONTENTS

SELLING SECURITYHOLDERS On February 2, 2024, we issued $402.5 million aggregate principal amount of notes in a private placement in reliance on an exemption from registration under the Securities Act of 1933, as amended, or the Securities Act. The initial purchasers of the notes in that offering resold the notes in offerings in reliance on an exemption from registration under Rule 144A of the Securities Act, including $87,500,000 to the selling securityholders. The following table sets forth certain information as of the date of this prospectus supplement, concerning the principal amount of notes beneficially owned that may be offered from time to time under this prospectus supplement by the selling securityholders named in the table. We prepared this table based on the information supplied to us by the selling securityholders named in the table and we have not sought to verify such information. This table only reflects information the selling securityholders provided us. Information concerning the selling securityholders may change from time to time and any changed information will be set forth in supplements to this prospectus supplement if and when necessary. To our knowledge, except as may be disclosed herein, none of the selling securityholders have, and within the past three years have not had, any position, office or other material relationship with us or any of our affiliates, other than the right to appoint a director and/or an observer to our board of directors and the beneficial ownership of our notes and ordinary shares. To our knowledge, none of the selling securityholders is a broker-dealer, nor at the time of the acquisition of our ordinary shares did any of the selling securityholders have direct or indirect agreements or understandings with any person to distribute any of our ordinary shares, including any ordinary shares represented by ADSs.

|                                                     |     | Notes           |     |                 |     |                    |     |            |     | Ordinary Shares |     |              |     |                    |     |            |
| Name                                                |     | Principal       
 Amount of       
 Notes           
 Beneficially    
 Owned           
 Prior to the    
 Offering        |     | Maximum         
 Principal       
 Amount at       
 Maturity of     
 Notes           
 Registered      
 Hereunder       
 for Sale        |     | Principal          
 Amount of          
 Notes Beneficially 
 Owned Upon